Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 62

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 62
---
 therefore, such information is not presented.

15

The following table presents the operating results of the Company's segment for the three and six months ended June 30, 2025, and 2024:Three months ended June 30,Six months ended June 30,2025202420252024Total revenues$25,881 $4,449 $46,282 $7,874 Less significant segment expenses:Research and development directly identified to programs2,339 6,242 4,700 13,453 Research and development not directly identified to programs1,094 4,279 1,991 9,345 Selling, general and administrative directly identified to programs6,439 3,834 14,000 7,696 Selling, general and administrative not directly identified to programs14,343 8,770 26,327 14,839 Other segment items:Impairment of intangible assets58,710 — 58,710 — Income tax expense2,199 70 3,381 — Interest income(2,257)(705)(2,975)(1,467)Depreciation and amortization expense1,651 1,562 3,300 3,124 Interest expense2,009 2,110 3,978 2,845 Other income, net (a)(135,353)(1,788)(138,738)(5,414)Segment net income (loss)$74,707 $(19,925)$71,608 $(36,547)(a) Other expense, net included in segment net income (loss) includes the gain on the sale of the PRV, foreign currency exchange gains and losses, cost of product revenue (excluding intangible asset amortization), fair value adjustment related to warrant and contingent value right (“CVR”) liabilities, fair value adjustment related to investments, and other overhead expenses.The Company holds long-lived assets in the United States of $2.6 million and $13.4 million as of June 30, 2025, and December 31, 2024, respectively. The Company holds long-lived assets in Europe of $0.4 million and $0.5 million as of June 30, 2025, and December 31, 2024, respectively.

D.    Inventories

The components of inventory are summarized as follows (in thousands):June 30,202